NEW YORK ( TheStreet) -- Shares of SciClone Pharmaceuticals (Nasdaq: SCLN) were gapping up Wednesday morning with an open price 18.3% higher than Tuesday's closing price. The stock closed at $5.24 Tuesday and opened today's trading at $6.20. The average volume for SciClone has been 213,600 shares per day over the past 30 days. SciClone has a market cap of $266.1 million and is part of the health care sector and drugs industry. Shares are up 22.1% year to date as of the close of trading on Tuesday. SciClone Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People's Republic of China and internationally. The company has a P/E ratio of 14.3, above the average drugs industry P/E ratio of 12.6 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates SciClone as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full SciClone Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping up? Get free SMS text alerts sent to you when the action happens by texting UP to 95370 or select from multiple alert options.
More from Markets
3 Earnings Reports Will Be Key for the Market Next Week
There is a good foundation for more positive action in the week ahead.
Stocks Finish Lower, Pulled Down by Boeing, Johnson & Johnson, Weak China Growth
Stocks declined as Boeing and Johnson & Johnson pulled shares down, while China posted its weakest quarterly economic growth rate in nearly three decades, returning investors' attention to the trade talks between Washington and Beijing.
Are Stock Investors Overreacting to China's GDP Lag? One Big Investor Thinks So
Stock investors should take a finer look at China's economy, UBS thinks.
American Express Beats Third-Quarter Estimates as Card Fees Set Record
Record-setting card fees help the credit card giant beat Wall Street's third-quarter earnings expectations.